Antigenemia pp65 assay and qualitative CMV DNA PCR assay for monitoring cytomegalovirus infection in allogeneic stem cell transplant recipients - Own findings;Monitorowanie infekcji CMV metoda̧ oceny antygenemii pp65 i DNA przy pomocy jakościowego PCR u chorych poddanych allogenicznej transplantacji komórek hematopoetycznych - Doświadczenia własne

Acta Haematologica Polonica

Volumn 34, Issue 3, 2003, Pages 339-346

  Pia̧tkowska Jakubas, Beata ^a   Zawilińska, Barbara ^a   Kopec J ^a   Rojek Zakrzewska, D ^a   Koprynia, M ^a   Polus, Anna ^b   Skotnicki, Aleksander B ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Pracowni Diagnostyki Molekularnej

Author keywords

Allogeneic transplantation; Antigenemia pp65; CMV DNA PCR; CMV infection

Indexed keywords

ACCURACY; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANALYTIC METHOD; ARTICLE; ASSAY; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DONOR; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; POLYMERASE CHAIN REACTION; RECIPIENT;

EID: 0346099430     PISSN: 00015814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Boeckh M. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy. Transplant Infect Disease 1999; 1: 165-178.
2. Boeckh M, Bowden RA, Gooley T, Myerson D, Corey L. Successful modification of a pp 65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood 1999; 93: 1781-1782.
3. Boivin G, Belanger R, Delage R, Beliveau C, Demers C, Goyette N, Roy J. Quantitative analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay and the Cobas Amplicor CMV monitor PCR test after blood and marrow transplantation. J Clin Microbiol 2000; 38: 4356-4360.
4. Caliendo A M, St George K, Kao SY, Allega J, Tan BH, La Fontaine R, Bui L, Rinaldo CR. Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay; clinical utility of the prototype Amplicor CMV monitor test in transplant recipients. J Clin Microbiol 2000; 38: 2122-2127.
5. Castagnola E, Miano M, Morreale G, Cristina E, Chierici M, Lanino E. Strategies for management of cytomgalovirus (CMV) infection after allogeneic bone marrow transplantation: the "doubling of baseline CMV pp65 antigenemia" and the cidofovir as rescue treatment approaches. Blood 2001; 98: 1627-1628.
6. Einsele H, Ehninger G, Hebart H, Wittkowsky KM, Schuler U, Jahn G, Mackes P, Herter M, Klingebiel M, Löffler J, Wagner S, Müller CA. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration of side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-2820.
7. Einsele H, Hebart CH, Kauffmann-Schneider C, Sinzger C, Jahn G, Bader P, Kinglebiel T, Dietz K, Löffler J, Bokemeyer C, Müller CA, Kanz L. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000; 25: 757-763.
8. Gerna GM, Revello G, Percivalle E, Morini F. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantification of human cytomegalovirus antigenemia. J Clin Microbiol 1992; 30: 1232-1237.
9. Hebart H, Brugger W, Grigoleit U, Gescheidle B, Loffler J, Schafer H, Kanz L, Einsele H. Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality. Blood 2001; 97: 2183-2185.
10. Hebart HC, Müller C, Löffler J, Jahn G, Einsele H. Monitoring of CMV infection: a comparison of PCR from whole blood, plasma - PCR, pp65 antigenemia and virus culture in patients after bone marrow transplantation. Bone Marrow Transpant 1996; 17: 861-868.
11. Mitchell SM, Fox JD, Tedder RS, Gazzard BG, Lightman S. Vitreous fluid sampling and viral genome detection for the diagnosis of viral retinitis in patients with AIDS. J Med Virol 1994; 43: 336-340.
12. Mori T, Okamato S, Matsuoka S, Yajima T, Watanabe R, Ishida A, Iwao Y, Maukai M, Hibi T, Ikeda Y. Risk-adapted therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Tranplant 2000; 25: 765-769.
13. Preiser WS, Brauninger R, Schwerdtfeger R, Ayliffe U, Garson JA, Brink NS, Franck S, Doerr HW, Rabenau HF. Evaluation of diagnostic methods for the detection of cytomegalovirus in recipients of allogeneic stem cell transplants. J Clin Virol 2001; 20: 59-70.
14. Solano C, Munoz I, Gutierrez A, Farga A, Prosper F, Garcia-Conde J, Navarro J, Gimeno C. Qualitative plasma PCR Assay (Amplicor CMV Test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation. J Clin Microbiol 2001; 39: 3938-3941.
15. The TH, van den Bergh AP, Harmsen MC, van der Bij W, van Son WJ. The cytomegalovirus antigenemia assay: a plea for standarization. Scand J infect Dis 1995; 99 (suppl): 25-29.
16. Winston DJ, Ho WG, Bartoni K, DuMond C, Ebeling DF, Buhles WC, Champlin RE. Ganciclovir prophylaxis of cytomegalovirus-infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 1993; 118: 179-184.